Wf 516 | 310392-93-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: Wf 516
• 英文别名: (2S)-1-[4-(3,4-dichlorophenyl)piperidin-1-yl]-3-[2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol monohydrochloride；1-Piperidineethanol, 4-(3,4-dichlorophenyl)-alpha-(((2-(5-methyl-1,3,4-oxadiazol-2-yl)-4-benzofuranyl)oxy)methyl)-, monohydrochloride, (alphaS)-；(2S)-1-[4-(3,4-dichlorophenyl)piperidin-1-yl]-3-[[2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-benzofuran-4-yl]oxy]propan-2-ol;hydrochloride
• CAS: 310392-93-9
• 化学式: C₂₅H₂₅Cl₂N₃O₄*ClH
• 分子量: 538.858
• InChiKey: HRNDUKHBCUTNAL-FERBBOLQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.14
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  84.8
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  1-butyl-4-(4-phenyl-1-piperidyl)pyridin-2-one 以82的产率得到Wf 516
  参考文献：
  名称：

  1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones

  摘要：

  本发明涉及新颖的化合物，特别是按照式（I）定义的新颖吡啶酮衍生物，其中所有基团在本申请和权利要求中都有定义。本发明的化合物是代谢型受体亚型2（“mGluR2”）的正向变构调节剂，对于与谷氨酸功能障碍有关的神经和精神障碍以及涉及代谢型受体亚型mGluR2的疾病的治疗或预防有用。特别是，这些疾病是从焦虑、精神分裂症、偏头痛、抑郁症和癫痫等中枢神经系统疾病中选择的。本发明还涉及制备这种化合物和组合物的制药组合物和方法，以及使用这种化合物预防和治疗涉及mGluR2的这些疾病。

  公开号：

  US09114138B2

文献信息

• 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
  申请人：Cid-Nunez Jose Maria

  公开号：US09114138B2

  公开（公告）日：2015-08-25

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及新颖的化合物，特别是按照式（I）定义的新颖吡啶酮衍生物，其中所有基团在本申请和权利要求中都有定义。本发明的化合物是代谢型受体亚型2（“mGluR2”）的正向变构调节剂，对于与谷氨酸功能障碍有关的神经和精神障碍以及涉及代谢型受体亚型mGluR2的疾病的治疗或预防有用。特别是，这些疾病是从焦虑、精神分裂症、偏头痛、抑郁症和癫痫等中枢神经系统疾病中选择的。本发明还涉及制备这种化合物和组合物的制药组合物和方法，以及使用这种化合物预防和治疗涉及mGluR2的这些疾病。
• USE OF PHENOXYPROPYLAMINE COMPOUNDS TO TREAT OR IMPROVE AT LEAST ONE DISORDER OR PARAMETER OF SLEEP
  申请人：Minerva Neurosciences, Inc.

  公开号：EP3925608A2

  公开（公告）日：2021-12-22

  Disclosed herein are compositions and methods for treating depression using compositions comprising a compound of formula I. Disclosed herein are compositions and methods for treating depression using compositions comprising phenoxypropylamine compounds and derivatives having selective affinity for and antagonistic activity against the 5-HT1A receptor, as well as 5-HT reuptake inhibitory activity. In addition, compositions and methods for treating depression using compositions comprising a compound of formula II are disclosed. Methods of treating or diminishing at least one symptom of depression in a human subject with a composition comprising a compound of the formula (I) or formula (II), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, are also disclosed.

  本文公开了使用包含式 I 化合物的组合物治疗抑郁症的组合物和方法。本文公开了使用包含对 5-HT1A 受体具有选择性亲和力和拮抗活性以及 5-HT 再摄取抑制活性的苯氧基丙胺化合物和衍生物的组合物治疗抑郁症的组合物和方法。此外，还公开了使用包含式 II 化合物的组合物治疗抑郁症的组合物和方法。还公开了用包含式（I）或式（II）化合物或其药学上可接受的盐、水合物或溶液的组合物治疗或减轻人体内至少一种抑郁症状的方法。
• PHENOXYPROPYLAMINE COMPOUNDS
  申请人：Mitsubishi Pharma Corporation

  公开号：EP1188747B1

  公开（公告）日：2005-09-07
• USE OF PHENOXYPROPYLAMINE COMPOUNDS TO TREAT DEPRESSION
  申请人：Minerva Neurosciences, Inc.

  公开号：EP2948143B1

  公开（公告）日：2021-05-05
• JP2008195654A
  申请人：——

  公开号：JP2008195654A

  公开（公告）日：2008-08-28